VolitionRX (NYSEAMERICAN:VNRX) released its quarterly earnings results on Monday. The medical research company reported ($0.11) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.01, Morningstar.com reports.
NYSEAMERICAN:VNRX opened at $3.92 on Wednesday. VolitionRX has a 12 month low of $1.67 and a 12 month high of $4.65.
In related news, Director Martin Charles Faulkes acquired 70,731 shares of the stock in a transaction dated Monday, June 10th. The stock was acquired at an average cost of $3.02 per share, for a total transaction of $213,607.62. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
VolitionRX Company Profile
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRX Limited is based in Singapore.
Featured Story: What is Compound Interest?
Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.